US OptionsDetailed Quotes
MRK240712C131000
- 0.01
- -0.06-85.71%
15min DelayClose Jul 12 15:59 ET
0.10High0.01Low
0.10Open0.07Pre Close14 Volume556 Open Interest131.00Strike Price37.00Turnover117.56%IV2.54%PremiumJul 12, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0182Delta0.0293Gamma12776.00Leverage Ratio-0.8264Theta0.0000Rho232.02Eff Leverage0.0006Vega
Merck & Co Stock Discussion
Sign in to post a comment
President Joe Biden, 81, has stated he remains committed to his re-election campaign despite slipping polling numbers and concerns about his recent public performances.
Reports suggest Biden acknowledged the importance of his upcoming appearances, though the White House denies this claim. His stumbling debate performance and questions about his mental acuity have caused panic within the Democratic Party, leading to speculation about a...
Reports suggest Biden acknowledged the importance of his upcoming appearances, though the White House denies this claim. His stumbling debate performance and questions about his mental acuity have caused panic within the Democratic Party, leading to speculation about a...
86
18
$Merck & Co(MRK.US$I think it’s just a temp pullback, it just broke the double-bottom line as well as the recent resistence simetanously. The pullback volume is also lower. Expecting new ATH.
5
$Merck & Co(MRK.US$ on the prowl for acquisitions up to $15 billion.
$Merck & Co(MRK.US$ already has an active partnership with $Janux Therapeutics(JANX.US$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US$ in which $Merck & Co(MRK.US$ already has a seat at the table.
$Merck & Co(MRK.US$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
$Merck & Co(MRK.US$ already has an active partnership with $Janux Therapeutics(JANX.US$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US$ in which $Merck & Co(MRK.US$ already has a seat at the table.
$Merck & Co(MRK.US$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
+1
9
🔥 3 PDUFA decisions this week! 👇
📌 This week’s PDUFAs:
$Merck & Co(MRK.US$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
📌 This week’s PDUFAs:
$Merck & Co(MRK.US$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
9
$Sarepta Therapeutics(SRPT.US$ : ELEVIDYS
$Harmony Biosciences(HRMY.US$ : WAKIX (pitolisant)
$Bristol-Myers Squibb(BMY.US$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE(ARGX.US$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co(MRK.US$ : Patritumab deruxtecan
$Verona Pharma(VRNA.US$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals(RCKT.US$ : KRESLADI (Marnetegragene autotemcel)
$Harmony Biosciences(HRMY.US$ : WAKIX (pitolisant)
$Bristol-Myers Squibb(BMY.US$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE(ARGX.US$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co(MRK.US$ : Patritumab deruxtecan
$Verona Pharma(VRNA.US$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals(RCKT.US$ : KRESLADI (Marnetegragene autotemcel)
14
$Merck & Co(MRK.US$ 🎉
FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine)
⇨ for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults 🫁
» CAPVAXIVE (V116) protects against most strains causing illness in adults over 50. 🛡️
» Effective in people who've never had a pneumococcal vaccine or already have one as demonstrated in Ph3 trials.
FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine)
⇨ for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults 🫁
» CAPVAXIVE (V116) protects against most strains causing illness in adults over 50. 🛡️
» Effective in people who've never had a pneumococcal vaccine or already have one as demonstrated in Ph3 trials.
10
1
$Merck & Co(MRK.US$ 121 this week?
1
Morning Movers
Gapping up
$Chegg(CHGG.US$ stock saw an impressive 18.01% increase after the education technology company announced a significant workforce reduction, cutting 23% of its global staff as a part of an extensive restructuring initiative.
$Merck & Co(MRK.US$ shares experienced a 1.11% uptick following the U.S. Food and Drug Administration's approval of the pharmaceutical giant's advanced vaccine designed to protect a...
Gapping up
$Chegg(CHGG.US$ stock saw an impressive 18.01% increase after the education technology company announced a significant workforce reduction, cutting 23% of its global staff as a part of an extensive restructuring initiative.
$Merck & Co(MRK.US$ shares experienced a 1.11% uptick following the U.S. Food and Drug Administration's approval of the pharmaceutical giant's advanced vaccine designed to protect a...
30
$Merck & Co(MRK.US$
👉 Key Highlights:
📍 FDA approves Merck’s Capvaxive vaccine for pneumococcal disease.
📍 Capvaxive protects against 21 strains of pneumococcus bacteria.
📍 First pneumococcal conjugate vaccine designed specifically for adults.
📍 Targets severe pneumococcal disease, including pneumonia and meningitis.
📍 150,000 U.S. adults hospitalized annually with invasive pneumococcal disease.
📍 Merck expects rapid uptake and significa...
👉 Key Highlights:
📍 FDA approves Merck’s Capvaxive vaccine for pneumococcal disease.
📍 Capvaxive protects against 21 strains of pneumococcus bacteria.
📍 First pneumococcal conjugate vaccine designed specifically for adults.
📍 Targets severe pneumococcal disease, including pneumonia and meningitis.
📍 150,000 U.S. adults hospitalized annually with invasive pneumococcal disease.
📍 Merck expects rapid uptake and significa...
2
Keep an eye on these recently announced M&As: 👀
$Merck & Co(MRK.US$ to acquire EyeBio
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Novartis AG(NVS.US$ to acquire Mariana Oncology
What companies will be next? 🤔
$Merck & Co(MRK.US$ to acquire EyeBio
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Novartis AG(NVS.US$ to acquire Mariana Oncology
What companies will be next? 🤔
4
No comment yet
White_Shadow :
104749672 : Informative
Mathew Yetter White_Shadow: T hey are both pigs!
aaron1999x : Trump FtW
71780680 : why would anyone want more[Sigh]...seams to me people like the kolaid
View more comments...